PMID- 31369642

OWN - NLM
STAT- In-Data-Review
LR - 20190801
IS - 1932-6203 (Electronic)
IS - 1932-6203 (Linking)
VI - 14
IP - 8
DP - 2019
TI - Clinical parameters affecting the therapeutic efficacy of empagliflozin in
patients with type 2 diabetes.
PG - e0220667
LID - 10.1371/journal.pone.0220667 [doi]
AB - We aimed to investigate the clinical factors affecting the therapeutic
effectiveness of the sodium-glucose cotransporter-2 inhibitor empagliflozin
in
patients with type 2 diabetes mellitus (T2DM). We reviewed the medical
records of
374 T2DM patients aged between 20 and 75 years who were prescribed
empagliflozin
10 mg or 25 mg as add-on therapy for more than 90 consecutive days. Changes
in
hemoglobin A1c (HbA1c) from baseline levels and the reduction in body weights
of
the study participants were assessed. We found that younger patients (</= 50
years), patients with the highest levels of HbA1c (>9%) at baseline, patients
with an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2,
and
patients with a shorter duration of T2DM (< 10 years) were more likely to
exhibit
a better glycemic response. Multivariate linear regression analysis revealed
that
a shorter duration of T2DM, higher baseline levels of HbA1c, and higher eGFR
were
positively associated with HbA1c reduction. Higher BMI and lower HbA1c levels
were predictors of a more significant reduction in body weight among patients
taking empagliflozin. The glucose-lowering effect of empagliflozin was more
evident in T2DM patients with higher baseline HbA1c levels, better renal
function, and shorter duration of T2DM.
FAU - Cho, Yun Kyung
AU - Cho YK
AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
AD - Department of Internal Medicine, Kangwon National University School of
Medicine,
Chuncheon, Republic of Korea.
FAU - Lee, Jiwoo
AU - Lee J
AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
FAU - Kang, Yu Mi
AU - Kang YM
AD - International Healthcare Center, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
FAU - Yoo, Jee Hee
AU - Yoo JH
AD - Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan
University
School of Medicine, Seoul, Republic of Korea.
FAU - Park, Joong-Yeol
AU - Park JY
AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
FAU - Jung, Chang Hee
AU - Jung CH
AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
FAU - Lee, Woo Je
AU - Lee WJ
AUID- ORCID: http://orcid.org/0000-0002-9605-9693
AD - Department of Internal Medicine, Asan Medical Center, University of Ulsan
College
of Medicine, Seoul, Republic of Korea.
LA - eng
PT - Journal Article
DEP - 20190801
PL - United States
TA - PLoS One
JT - PloS one
JID - 101285081
SB - IM
COIS- The authors have declared that no competing interests exist.
CRDT- 2019/08/02 06:00
PHST- 2019/05/01 00:00 [received]
PHST- 2019/07/19 00:00 [accepted]
PHST- 2019/08/02 06:00 [entrez]
AID - 10.1371/journal.pone.0220667 [doi]
AID - PONE-D-19-12374 [pii]
PST - epublish
SO - PLoS One. 2019 Aug 1;14(8):e0220667. doi: 10.1371/journal.pone.0220667.
eCollection 2019.